NCT05351489View on ClinicalTrials.gov

Effect of Two Different Doses of Intrathecal Dexmedetomidine as Adjuvant in Elderly Patients Undergoing HoLEP

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

October 30, 2023

Study Completion Date

December 31, 2024

Conditions
Transurethral Resection of Prostate
Interventions
DRUG

Dexmedetomidine

Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .

Trial Locations (1)

050

Urology and nephrology center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER